Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › niraparib

niraparib

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of niraparib

21 trials tracked of niraparib: 1 in phase 3 or 4 and 1 with published results. The most-cited published study has 75 citations.

21Trials tracked
1Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 3 1 Phase 2 15 Phase 1 5
  1. Phase 3 Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants With Advanced/Metastatic Non-Small Cell Lung Cancer Completed · 75 cited
  2. Phase 2 Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer Completed
  3. Phase 2 A Study of Niraparib Combined With Bevacizumab Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy Completed
  4. Phase 2 European Trial on Enhanced DNA Repair Inhibition in Ovarian Cancer Completed
  5. Phase 2 Testing the Addition of a New Anti-Cancer Drug, Niraparib, to the Usual Treatment (Hormone and Radiation Therapy) for Prostate Cancer With a High Chance of Recurring Completed
  6. Phase 2 Japan Phase 2 Study of Niraparib in Participants With Advanced, Relapsed Ovarian Cancer Completed
Show 15 more trials
  1. Phase 2 Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer Participants Completed
  2. Phase 2 An Efficacy and Safety Study of Niraparib in Men With Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies Completed
  3. Phase 2 A Study to Evaluate the Efficacy and Safety of Novel Treatment Combinations in Participants With Ovarian Cancer Completed
  4. Phase 2 Japan Phase 2 Study of Niraparib (Maintenance Therapy) in Participants With Relapsed Ovarian Cancer Completed
  5. Phase 2 Niraparib + Dostarlimab + RT in Pancreatic Cancer Completed
  6. Phase 2 Study Evaluating the Efficacy of Niraparib and Dostarlimab (TSR-042) in Recurrent/Metastatic HNSCC Completed
  7. Phase 2 A Study of Niraparib in Patients With Ovarian Cancer Who Have Received Three or Four Previous Chemotherapy Regimens Completed
  8. Phase 2 A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001) Completed
  9. Phase 2 Study to Evaluate the Safety and Efficacy of TSR-042, Bevacizumab, and Niraparib in Participants With Recurrent Ovarian Cancer Completed
  10. Phase 2 Niraparib and Dostarlimab for the Treatment of Germline or Somatic BRCA1/2 and PALB2 Mutated Metastatic Pancreatic Cancer Completed
  11. Phase 1 Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042 Completed
  12. Phase 1 Evaluation of the Safety and Tolerability of Niraparib With Everolimus in Advanced Gynecologic Malignancies and Breast Completed
  13. Phase 1 A Study of Niraparib as Single Agent in Participants With Advanced Solid Tumors Completed
  14. Phase 1 Study Evaluating the Antitumor Activity and Safety of Niraparib as Neoadjuvant Treatment in Participants With Breast Cancer Completed
  15. Phase 1 Pharmacokinetic and Safety Study of Niraparib With Normal or Moderate Hepatic Impairment Patients Completed

Showing the 21 most-cited and recently-updated of 21 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Systematic review uses PBPK modeling to guide niraparib dose adjustments in hepatic impairment
Drug Pipeline Sys. Review
Systematic review uses PBPK modeling to guide niraparib dose adjustments in hepatic impairment New Dose Rules for Niraparib in Liver Disease Protect Patients
This systematic review uses physiologically based pharmacokinetic (PBPK) modeling to predict optimal niraparib dosing in patients with hepat…
A smart computer model now shows how to safely lower niraparib doses for cancer patients with liver disease, protecting them from harmful si…
Frontiers May 11, 2026
Niraparib plus abiraterone and prednisone shows mixed results in HRR-mutated mCRPC
Drug Pipeline Cohort
Niraparib plus abiraterone and prednisone shows mixed results in HRR-mutated mCRPC New drug combo extends life for some prostate cancer patients
This retrospective cohort study of 5 patients with HRR-mutated metastatic castration-resistant prostate cancer evaluated niraparib plus abir…
Some men with advanced prostate cancer are living longer with a powerful new drug combo, even when they’re older or too weak for harsh treat…
Frontiers Apr 28, 2026